A Multifaceted Role of Tryptophan Metabolism and Indoleamine 2,3-Dioxygenase Activity in Aspergillus fumigatus–Host Interactions

Tsokyi Choera1, Teresa Zelante2, Luigina Romani2 and Nancy P. Keller1,3*

1Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, United States, 2Department of Experimental Medicine, University of Perugia, Perugia, Italy, 3Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, United States

Aspergillus fumigatus is the most prevalent filamentous fungal pathogen of humans, causing either severe allergic bronchopulmonary aspergillosis or often fatal invasive pulmonary aspergillosis (IPA) in individuals with hyper- or hypo-immune deficiencies, respectively. Disease is primarily initiated upon the inhalation of the ubiquitous airborne conidia—the initial inoculum produced by A. fumigatus—which are complete developmental units with an ability to exploit diverse environments, ranging from agricultural composts to animal lungs. Upon infection, conidia initially rely on their own metabolic processes for survival in the host’s lungs, a nutritionally limiting environment. One such nutritional limitation is the availability of aromatic amino acids (AAAs) as animals lack the enzymes to synthesize tryptophan (Trp) and phenylalanine and only produce tyrosine from dietary phenylalanine. However, A. fumigatus produces all three AAAs through the shikimate–chorismate pathway, where they play a critical role in fungal growth and development and in yielding many downstream metabolites. The downstream metabolites of Trp in A. fumigatus include the immunomodulatory kynurenine derived from indoleamine 2,3-dioxygenase (IDO) and toxins such as fumiquinazolines, gliotoxin, and fumitremorgins. Host IDO activity and/or host/microbe-derived kynurenines are increasingly correlated with many Aspergillus diseases including IPA and infections of chronic granulomatous disease patients. In this review, we will describe the potential metabolic cross talk between the host and the pathogen, specifically focusing on Trp metabolism, the implications for therapeutics, and the recent studies on the coevolution of host and microbe IDO activation in regulating inflammation, while controlling infection.

Keywords: Aspergillus fumigatus, tryptophan metabolism, IDO, kynurenines, toxins, non-ribosomal peptides, peripheral tolerance, Th17 cells

INTRODUCTION

Aspergillus fumigatus is a saprophytic fungus that has a worldwide distribution. The asexual spores (called conidia) are ubiquitous and individuals inhale hundreds of spores daily. While most inhaled conidia are cleared by individuals with a healthy immune system, A. fumigatus can act as an opportunistic human pathogen in individuals with altered immune functions. Disease presentation can vary on the status of the host’s immune system; A. fumigatus can cause allergic bronchopulmonary aspergillosis, a severe allergic response, in the hyper-immune, or the fatal invasive growth
invasive pulmonary aspergillosis (IPA) in the hypo-immune, or in individuals with other susceptibilities such as patients unable to mount the necessary oxidative defenses such as in individuals with chronic granulomatous disease (CGD) (1).

The manifestation of disease is dependent not only on the host's immune status but also fungal factors including strain heterogeneity (2). A. fumigatus growth in the mammalian lung, following survival of resident pulmonary defenses, requires the fungus to adapt to a hypoxic and nutritionally scarce environment. Aspergillus mutants unable to synthesize primary metabolites necessary for growth are generally impaired in virulence. For example, deletion of cpcA, a transcription factor that globally modulates amino acid biosynthesis in the fungus led to a less virulent phenotype in a murine model of IPA (3). Additional studies have shown that mutants in sulfur utilization (4), uracil/uridine synthesis (5), zinc uptake, iron acquisition, and many more (6, 7) are also decreased in virulence.

To complicate disease progression further, there is an alarming rise in antifungal resistance strains of A. fumigatus (8, 9). Therefore, an understanding of A. fumigatus and host metabolic pathways is important in identifying nutrient limitations. One critical metabolic pathway is the biosynthesis of aromatic amino acids [AAAs, tryptophan (Trp), phenylalanine, and tyrosine], which are required not only for growth of A. fumigatus but are also precursors for several toxins (Table 1). The host relies on dietary sources for all AAAs while A. fumigatus synthesizes all three. However, the host and A. fumigatus both possess AAA catabolic enzymes. In particular, one key enzyme important in immune homeostasis is indoleamine 2,3-dioxygenase (IDO), which converts Trp to kynurenine and related metabolites in both organisms. Historically, host IDOs activity has been described as an effective antimicrobial control for pathogens that are natural Trp auxothrophs such as Staphylococcus aureus, Chlamydiaspp., and Toxoplasma gondii, presumably by Trp starvation (10). However, A. fumigatus can synthesize its own Trp and thus the Trp starvation may not be an effective pathogen control for those microbes able to synthesize their own Trp pools. Although, IDOs also play additional roles in host defenses through modifying kynurenine levels and subsequent cytokine responses as described below. In this review, we will summarize the recent studies describing the anabolic and the catabolic pathways of Trp metabolism, the implications for therapeutics, and the host–pathogen interaction.

### TABLE 1 | Aspergillus fumigatus non-ribosomal peptides containing aromatic amino acids (AAAs) in their peptide structure.

| Toxin           | AAA* Interaction with host†‡  |
|-----------------|--------------------------------|
| Fumigaclavine C°| Tryptophan (Trp) Downregulation of Th1 cytokines including TNF-α, IL-1β, and IL-17A. Induction of host cell apoptosis. Decrease activation of caspase-1 |
| Fumiquinazoline C°| Anthranilate Tryp Cytotoxic |
| Fumisooquin*   | Tyrosine Nothing reported |
| Fumitemporin*  | Trp Neurotoxic and produces tremors in mice |
| Tryprostatin A°| Verruculogen Vital in a steroid murine model of IPA |
| Verruculogen°  | Phenylalanine | Virulent in a steroid murine model of IPA |
| Gliotoxin°     | Tryptophan (Trp) | Overexpression resulted in a significantly higher virulence in a neutropenic murine model of IPA |

IPA: invasive pulmonary aspergillosis; HNEC: human nasal epithelial cells.

*Only the AAA is designated. Other amino acids are also in the structure of these metabolites.†|‡|Bioactivity and host interactions based on the following sources: °|11, 12; °|13; °|14; °|15, 16; °|17; °|18, 19; °|7, 20; °|21, 22.

### Trp SYNTHESIS AND POTENTIAL THERAPEUTIC TARGETING

Chorismic acid derived from the shikimic acid pathway is a key intermediate in producing Trp, phenylalanine (Phe), and tyrosine (Tyr) in microorganisms including A. fumigatus (Figure 1). Trp and Phe are classified as essential amino acids, whereas mammals acquire them from diet, whereas Tyr is synthesized via the hydroxylation of Phe (23, 24). The absence of the AAA biosynthetic enzymes and the low bioavailability of Trp in humans makes the Trp biosynthetic enzymes attractive targets for antifungals (25).

### Fungal Trp Anabolic Pathway

Aromatic amino acid synthesis has been extensively studied in Saccharomyces cerevisiae and provides the basis for the functional characterization of orthologous enzymes in filamentous fungi (23, 24, 26–28). The shikimic acid pathway is a 7-enzymatic step reaction that initiates with two substrates, phosphoenolpyruvate (PEP) and erythrose-4-phosphate (E4P), which are intermediates of glycolysis and pentose phosphate pathways, respectively (29) (Figure 1). The first step of the shikimic acid pathway is catalyzed by 3-deoxy-d-arabinoheptulosonate 7-phosphate (DAHP) synthase to convert PEP and E4P to DAHP. In S. cerevisiae and A. nidulans, there are two DAHP synthases, Ar03 and Ar04, which are allosterically inhibited by phenylalanine and tyrosine, respectively (24). Steps 2–6 in filamentous fungi such as A. nidulans and A. fumigatus are completed by the pentafunctional enzyme Ar0M, or Ar01 in the model organism S. cerevisiae (30). The shikimate pathway culminates in the production of chorismic acid synthesized by the enzyme chorismate synthase (Ar0B) in 5-enolpyruvylshikimate-3-phosphate (EPSP) (31).

The synthesis of Trp from chorismate is initiated by an anthranilate synthase (AS), which converts chorismate to anthranilate, followed by three enzymatic steps as presented in Figure 1 with the respective functions outlined in Table 2. AS(s) in S. cerevisiae have been characterized, and it consists of two subunits: anthranilate synthase subunit I (AAS-I), which binds chorismate and is subject to feedback inhibition by Trp and anthranilate synthase.
subunit II (AAS-II) which is a glutamine amidotransferase (32). The A. nidulans trpC, an AAS-II encoding gene, was characterized in 1977 (33) and found exchangeable with an A. fumigatus trpC in 1994 (34). Wang et al. (28) recently characterized trpE, the AAS-I encoding gene in A. fumigatus. Wang et al. (28) explored the functions of two putative AAS-IIs termed trpE and icsA by creating null mutants. The deletion of trpE led to a Trp auxotrophic strain, whereas the deletion of icsA did not. To ensure that icsA did not serve a redundant role for Trp synthesis, the group overexpressed icsA in a trpE deletion and showed that the overexpression of icsA does not reverse the Trp auxotrophy concluding that TrpE is the only AS in A. fumigatus. Interestingly, the group showed that IcsA is an active enzyme in A. fumigatus as the precursor-chorismate pool is altered in the absence or overproduction of IcsA; however, the product is not known (28). Sasse et al. also confirmed that deletion of trpE (they termed trpA) results in an A. fumigatus Trp auxotrophy (31).

**The Shikimate Pathway As Potential Antifungal Targets**

Currently, there are four major classes of antifungals: azoles and amphotericin B targeting ergosterol, 5-fluorocytosine targeting DNA synthesis, and echinocandins targeting cell wall synthesis. These antifungals either exhibit high toxicity to the mammalian cell (particularly amphotericin B and 5-fluorocytosine) or lose efficacy due to the emergence of drug resistant strains (azoles and echinocandins) (9). With A. fumigatus being a eukaryotic pathogen and sharing many proteins with mammalian hosts, there are limitations to developing effective and safe antifungals and therefore a great need for treatments that are fungal specific. Since Trp is a human-essential amino acid and the enzymes in the biosynthesis are fungal specific, several studies have suggested utilizing and finding drugs to target the enzymes of this pathway (35–38).

Targeting essential amino acid pathways have already shown potential for new classes of antifungals. Several groups have explored inhibitors of genes or enzymes involved in methionine biosynthesis. Azoxybacillin, a compound isolated from B. cereus targets methionine biosynthesis by interfering with expression of homoserine transacetylase and sulfite reductase encoding genes (39–41). Whereas azoxybacillin displayed a broad spectrum antifungal activity in vitro, in vivo activity was low possibly due to bioavailability in the host (41). R1-331, a natural product from Streptomyces akiyoshiensis, is an effective inhibitor of homoserine dehydrogenase involved in both methionine and threonine biosynthesis (42, 43). Yamaguchi et al. show that R1-331 was active against medically important fungi such as Candida albicans and Cryptococcus neoformans and proved to be effective in the treatment of systemic murine candidiasis (42, 44).

Compounds targeting AAA pathways are limited with the most famous being the herbicide Roundup, where the active ingredient glyphosate inhibits EPSP synthase, one of the first enzymes initiating the shikimate pathway (45) (Figure 1). Glyphosate has shown to inhibit growth of several fungi including Candida maltose (46), Pneumocystis (47), and Cryptococcus neoformans where glyphosate delayed fungal melanization in vitro and in vivo and prolonged mice survival during infection (48). Another inhibitor of AAA pathway is a fluorinated anthranilate moiety, 6-FABA, which targets the TrpE enzyme and showed bactericidal activity when used on Mycobacterium tuberculosis (49). The studies of

---

**Figure 1** | Tryptophan anabolism of Aspergillus fumigatus. [Modified from that of Wang et al. (28)]. Solid arrows indicate characterized reaction as being present in A. fumigatus with product detected. Dashed arrows indicate uncharacterized reactions; however, putative orthologs are present in A. fumigatus.
Table 2 | Aspergillus fumigatus tryptophan (Trp) metabolism genes and putative protein function.

| Protein Ortholog in Saccharomyces cerevisiae | Gene name in A. fumigatus | Protein functiona Ortholog in mammals |
|--------------------------------------------|--------------------------|--------------------------------------|
| **Chorismate biosynthesis**                |                          |                                      |
| AroF | Arc3 | Afu1g02110 | DAHP synthase                            | –                  |
| AroG | Arc4 | Afu7g04070 | –                                        | –                  |
| AroM | Arc1 | Afu1g13740 | EPSP synthase                            | –                  |
| AroB | Arc2 | Afu1g09640 | Chorismate synthase                      | –                  |
| **Aromatic amino acid (AAA) biosynthesis** |                          |                                      |
| TrpE | Trp2 | Afu8g12580 | Anthranilate synthase                    | –                  |
| TrpC | Trp3 | Afu1g13090 | –                                        | –                  |
| TrpD | Trp4 | Afu4g11980 | Anthranilate phosphoribosyltransferase   | –                  |
| TrpC | Trp1 | Afu1g13090 | Phosphoribosylanthranilate isomerase     | –                  |
| TrpB | Trp5 | Afu2g13250 | Trp synthase                             | –                  |
| IcsA – | –   | Afu8g12110 | Isochorismate synthase                   | –                  |
| AroC | Aro7 | Afu5g13130 | Chorismate mutase                        | –                  |
| PheA | Phe2 | Afu5g06900 | Prephenate dehydratase                   | –                  |
| TyrA | Tyr1 | Afu2g10450 | Prephenate dehydrogenase                 | –                  |
| AroH | Aro8 | Afu2g13630 | AAA transaminase                         | –                  |
| AroL | Aro9 | Afu5g02290 | –                                        | –                  |
| **Trp degradation**                        |                          |                                      |
| IdOA | Bna2 | Afu1g14250 | Indoleamine 2,3-dioxygenases             | IDO1               |
| IdOB | Bna2 | Afu4g09830 | –                                        | IDO2               |
| IdOC | Bna2 | Afu7g02010 | –                                        | TDO                |
| FmdS | Bna7 | Afu1g09960 | Kynurenine formamidase                   | AFMID              |
| Bna4 | Bna4 | Afu6g07340 | Kynureninase                             | KNU                |
| Bna5 | Bna5 | Afu4g09840 | –                                        | LAAD               |
| AroH | Aro8 | Afu2g13630 | AAA transaminase                         | –                  |
| AroL | Aro9 | Afu5g02290 | –                                        | –                  |
| Aada | Aos2 | Afu3g02240 | Trp carboxylase                          | AADC               |
| MaoN – | –   | Afu3g00100 | Monoamine oxidase                        | MAOA               |
| AldA | Ald4 | Afu2g07200 | Aldehyde dehydrogenase                   | ALDH2              |
| Ald5 | Ald5 | Afu7g01000 | –                                        | –                  |

aPrediction of protein function based on AspGD (http://www.aspgd.org/) and KEGG (http://www.genome.jp/kegg/kegg2.html).

DAHP synthase, 3-deoxy-D-arabinoheptulosonate 7-phosphate synthase; EPSP synthase, enolpyruvylshikimate-3-phosphate synthase; AFMID, arylformamidase; KNYU, kynureninase; LAAD, l-amino-acid oxidase; AADC, aromatic-l-amino-acid decarboxylase, MAOA, monoamine oxidase; ALDH2, aldehyde dehydrogenase family.

These inhibitors suggest that the Trp biosynthetic pathway could be fruitful in future antifungal drug design.

The value of AAA pathways as drug targets is supported by the findings that AAA auxotrophic mutants are less virulent in animal infection models. Sasse et al. explored the possibility of these pathways as potential drug target by testing the virulence of several AAA auxotrophic mutants in a murine IPA model (31). This study demonstrated that AroM (Figure 1) was required for A. fumigatus viability. The group also constructed a conditional AroB repression strain that was attenuated virulence. Both a Trp auxotroph (TrpE mutant) and Tyr/Phe auxotroph (AroC mutant) were severely attenuated in virulence for pulmonary infection. Interestingly, the group also unveiled a putative difference in AAA distribution within the host by conducting a systemic infection showing that in a bloodstream infection the TrpE and the AroC mutants although less virulent, can establish some infection (31). Taken together, these results suggest that inhibitors of AAA biosynthetic pathways can potentially be used against A. fumigatus as a standalone treatment in a localized pulmonary infection or as an additive treatment in a systemic infection. The result of the bloodstream infection observed by Sasse et al. also suggests that there are mechanisms for the fungus to sense Trp in its environment and utilize it. In S. cerevisiae, the Trp specific permease, Tat2, is required for Trp uptake in yeast (50) and its closest homolog in A. fumigatus (Afu7g04290) is upregulated during fungal encounters with neutrophils (51) and dendritic cells (52). In A. nidulans, the G-protein coupled receptor (Gpr) H may be responsible for sensing Trp and glucose and GprH is conserved in A. fumigatus (53, 54). Perhaps, for a systemic infection, inhibition of specific peremeses or development of a GprH antagonist would be useful in reducing infections by Aspergillus.

CATABOLIC Trp METABOLITES IN FUNGI AND HOST

Although the anabolic Trp pathway is absent in mammals, the common catabolic pathways exist in the mammalian host with possession of the same enzymes as A. fumigatus (Afu7g04290) is upregulated during fungal encounters with neutrophils (51) and dendritic cells (52). In A. nidulans, the G-protein coupled receptor (Gpr) H may be responsible for sensing Trp and glucose and GprH is conserved in A. fumigatus (53, 54). Perhaps, for a systemic infection, inhibition of specific peremeses or development of a GprH antagonist would be useful in reducing infections by Aspergillus.
**Fungal Trp Catabolism**

There are three putative pathways (Figure 2; Table 2) for the degradation of Trp in *A. fumigatus*. The kynurenine branch is catalyzed by IDOs that convert Trp into formylkynurenine. In *A. fumigatus*, there are 3 putative *ido* genes: *idoA*, *idoB*, and *idoC*, the orthologs of *A. oryzae* *ido*α, *ido*β, and *ido*γ, respectively (55). Enzymatic studies of *Aspergillus oryzae* IDO enzymes suggest two of the three enzymes, IDOα and IDOβ, may participate in Trp degradation as they have a higher affinity of its substrate. However, the recent study by Wang et al., suggested IDOβ might be the more dominant enzyme than IDOα as determined by gene expression of *A. fumigatus* grown on Trp amended media (28). Additionally, *idoC* gene expression was slightly induced by the addition of Trp, but the authors note that IDOc had a closer relationship to bacterial IDOs than to fungal IDOs (28, 55). In *S. cerevisiae*, formylkynurenine is further oxidized to the immunomodulatory product kynurenine by a kynurenine formamidase denoted as Bna7, which has been described in *A. nidulans* and is predicted to be involved in NAD (+), biosynthesis (56). The kynurenine branch in fungi is involved in the de novo biosynthesis of NAD (+), a coenzyme that is required for oxidation-reduction reactions (57).

Tryptophan can also be metabolized via the indole pyruvate pathway, initiated through the transamination of Trp by aromatic
aminotransferases (termed Aro8 and Aro9 in *S. cerevisiae*). These aromatic aminotransferases are also involved in the synthesis of Phe and Tyr in *S. cerevisiae*, and their orthologs are present in *A. fumigatus* (28). In *S. cerevisiae*, the deletion of both Aro8 and Aro9 results in Phe and Tyr auxotrophies (24, 58, 59). In *Candida* spp., where filamentation and pigment production play a role in virulence, the products of these enzymes have been described to influence both phenotypes. The deletion of aro8 in *C. glabrata* results in a reduced pigment production and leads to an increased sensitivity to hydrogen peroxide (27). The aro8 and aro9 mutants of *C. albicans* results in a decreased conversion of Trp to indole acetaldehyde, which is formed via decarboxylation of indole pyruvate. Filamentation of *C. albicans* increased with the exposure to indole acetaldehyde (60).

Indole acetaldehyde can also be produced via the third putative product of Trp degradation: tryptamine. Tryptamine is most famously known as the active compound in psilocybin and for its similarity to serotoninons (61). Although the production of tryptamine has yet to be described in *A. fumigatus*, the downstream product of the tryptamine and indole pyruvate pathway, indole acetic acid has been described in several *Aspergillus* spp. including *A. fumigatus* (62, 63). Downstream metabolism of kynurenine, indole pyruvate, and tryptamine has not been explored further, but *A. fumigatus* does possess putative enzymes for the re-synthesis of anthranilate, the precursor to Trp (as denoted in Figures 1 and 2).

### AAA Incorporation into *Aspergillus* Toxins

Many filamentous fungi, including *A. fumigatus*, produce bioactive small molecules that can have detrimental impacts on human health. Subsets of these toxins are small peptides synthesized by non-ribosomal peptide synthetases (NRPS). Several pathogenic *Aspergillus* species synthesize AAA derived peptides including gliotoxin (*Phe* and serine) (64), fumiquinazoline (*Trp*, Anthranilate, and Alanine) (13), fumigaclavine (*Trp*) (65), fumitremorgin (*Trp* and Proline) (66), hexadecydroastechrome (*Trp* and Alanine) (21), fumisoquin (Tyr, Serine, and Methionine) (14), DPP-IV inhibitor WYK-1 (*Trp*, Tyr, and Leucine) (67), cyclopiazonic acid (*Trp*) (68) and benzomalvin (*Phe* and Anthranilate) (69). Table 1 summarizes the known AAA derived secondary metabolites of *A. fumigatus* and their effect on the host.

Although, fumiquinazolines have yet to be assessed for virulence in an animal model, they are known to have cytotoxic properties (13). Fumigaclavines have been described to have immunosuppressive properties in several studies including the suppression of antifungal cytokines such as TNFa, IL-17, and IFN-γ (12). Fumitremorgin, verruculogen, and tryprostatin—all related products of the fumitremorgin pathway—induce tremorgenic activity in mice and act on the central nervous system (15, 66, 70, 71). Mutants in the hexadecydroastechrome pathway (21) and gliotoxin (20, 21) pathways have altered virulence in murine IPA models. Decreased virulence of the *gliP* mutant (GliP is the NRPS required for gliotoxin synthesis) is dependent on host immune status [reviewed in Ref. (7)]. Overexpression of hasA encoding the hexadecydroastechrome transcription factor and thus leading to increased hexadecyroostechrome production was more virulent than wild type *A. fumigatus* in a neutrophenic model of IPA (21). Although the exact mechanism underlying the increased virulence of the OE:hasA strain is unknown, iron homeostasis and cross talk between metabolic pathways may contribute to the increased virulence of OE:hasA (22). These studies highlight the potential contribution of AAA derived toxins in virulence of *A. fumigatus*.

### Host Trp Catabolism via IDO

The function of host IDO during mammalian infection was originally thought to center on the anti-proliferative effects of pathogenic microorganism via deprivation of Trp exerted by the host. IDO is up-regulated by interferon gamma (IFNγ) and depletes Trp (the least abundant essential amino acid) to inhibit pathogen expansion (72, 73), as demonstrated in the constraint of chlamydial growth (74). Numerous studies have since implicated IDO activity as important in fungal infections and have reported the relative outcomes of IDO expression on disease progression (Table 3). Accumulating data continues to support that IDO participates in the host–pathogen interaction in human epithelial cells; therefore, the co-evolution of host and microbe Trp metabolism has been investigated (75). The current consensus is that IDO activation is pivotal in regulating inflammatory processes directly.
via Trp depletion and indirectly via the IDO-mediated release of Trp catabolic secondary metabolites (namely, kynurenines).

Dietary Trp is catabolized by two different IDO protein isoforms, IDO1 and IDO2 that are expressed by immune cells, and TDO (Trp 2,3-dioxygenase) that is mainly expressed in the liver. Cells involved in the innate processes of the anti-microbial defense, such as dendritic cells (DCs), neutrophils, and macrophages express IDO1 upon microbial encounter mainly via toll-like receptor stimulation. How fungi specifically induce IDO expression is not known; however, induction by other pathogens is associated with pathogen associated molecular patterns, including lipopolysaccharides and CpG oligodeoxynucleotides (78, 90–92), underlining a role for kynurenine metabolism in microbial-induced inflammatory processes.

**IDO-Mediated Tolerance: Impacts on Antimicrobial Responses**

Evolutionary studies have shown that the host immune defense against microbes is characterized by three different mechanisms: avoidance, resistance, and tolerance (93). Modules of immunity provide resistance to limit pathogen burden and tolerance and host damage caused by the immune reaction *per se*. However, the inflammatory reaction, although largely considered beneficial for its antimicrobial functions, may also contribute to pathogenicity. Thus, rescue from infection pathology may not only depend on microbial colonization (and inactivation of resistance mechanisms) but also on the resolution of tissue inflammatory pathology through tolerogenic responses to pathogens (94).

Studies using a mouse model of mucosal or invasive *C. albicans* infection found that systemic inhibition of IDO *in vivo* reduced gastrointestinal inflammation and unexpectedly, elevated the levels of fungal colonization compared to control mice (77). Notably, tolerogenic responses toward *C. albicans* were abrogated when IDO was antagonized *in vivo*, as shown in various models of inflammatory disorders (95, 96). As with *C. albicans*, IDO and kynurenine production during *A. fumigatus* infection contributes to fungal pathogen eradication and the regulation of an unacceptable level of tissue damage (97). Indeed, IDO can increase kynurenine host levels to induce adaptive Treg expansion while limiting Th17 polarization (83, 96). In this context, the Th17 pathway, which downregulates Trp catabolism, may instead favor pathology and better explain the paradoxical correlation between fungal infection and chronic inflammation (98).

Another example of this paradox was demonstrated in the context of CGD, in which an NADPH oxidase defect results in reduced host production of antimicrobial ROS and extreme susceptibility to *Aspergillus* infections (1, 83). Although human studies have excluded a role for IDO in CGD (99), further investigations into the IDO pathway are warranted as such studies have failed to demonstrate functional IDO activity at sites of chronic inflammation. Measures of IDO functional activity during IPA have, however, been made in mouse models, and implicate defective IDO activity as a key mediator of chronic inflammation in CGD (83). An exaggerated Th17 pulmonary response was associated with reduced fungal clearance in mouse models of CGD that develop IPA. Here, reduced IDO function was directly related to NADPH/ROS deficiency, as ROS is essential for IDO catalytic activity in mammals (100). ROS deficiency as a result of reduced NADPH function, significantly enhanced IL-17 inflammation and fungal germination in the lung, thus further reducing neutrophil-mediated antimicrobial activities (83).

Since regulation of homeostasis and peripheral tolerance are extremely important in prevention of invasive Aspergillosis or allergy to *Aspergillus* antigens (97, 101), the role of IDO has been extensively studied in this model of fungal infection (81, 82, 102). These studies highlight the induction of the IDO metabolic pathway at different site of fungal colonization as keratinocytes or lung as well as the important anti-inflammatory activity of IDO in the tissue microenvironment (80–82, 84).

**Aryl Hydrocarbon Receptor (AhR) Activation by IDO Metabolites in Mammals: Biological Consequences**

The AhR is a ligand-activated transcription factor first identified for its role during embryonic development and induction of xenobiotic metabolizing enzymes as a response to environmental toxins, such as dioxin (103). More recently, AhR has been shown to play a critical role in immunity by acting as an immune modulator during fungal infection (85). The connection between the AhR and the immune response lies in part in the endogenous AhR ligands, which comprise many Trp metabolites, including kynurenine (104). Microbial Trp-derived metabolites can activate the AhR, leading to adjustments in the immune response that may hinder disease development (105). The AhR–IDO axis has been recently demonstrated in fungal infection, highlighting a role for IDO-derived metabolites to trigger AhR target genes (85, 106). For example, one AhR target gene, *Il22*, has been widely studied in the context of fungal/microbial infections (105, 107–109). AhR activation by IDO metabolites can also mediate the expansion of peripheral Treg with anti-inflammatory properties. Using IDO-deficient mice, increased pulmonary disease caused by *Paracoccidioides brasiliensis* was associated with decreased Treg expansion and reduced AhR protein expression (85). In murine models of IPA, distinct Treg populations capable of mediating anti-inflammatory effects expand following exposure to *Aspergillus* conidia (97). Late in infection, tolerogenic adaptive Treg (with shared phenotypic identity with the Treg controlling autoimmune diseases or diabetes) produce IL-10 and TGFβ, inhibit Th2 cells, and prevent an allergic reaction to *Aspergillus* (97).

**CONCLUSION**

The interplay of Trp metabolic pathways and fungal/host interactions is intriguing with many unanswered questions of the exact nature of crosstalk of shared metabolites and consequences of activation of Trp degradative pathways. In *Aspergillus* infections in particular, not only does the pathogen synthesize and degrade Trp but it also can utilize this amino acid (and its precursor anthranilate or the other two AAAs Tyr and Phe) to yield several potentially damaging toxins (Table 1). Also, as both host and *Aspergillus* share catabolic IDO pathways, it is unclear which
organism may generate immunomodulatory Trp degradation products and if they respond to each other's products (e.g., kynurenine). Development of A. fumigatus IDO mutants for investigation of disease development could yield valuable information on this front. The research on the expression host IDOs exhibit the importance of an extremely coordinated immune response to mount the right inflammatory response for clearance of spores. However, while an increased IDO expression in the host can control inflammation, the suppression of the IDO-regulated antifungal Th17 responses can favor fungal growth. In this context, it will be critical to explore the entire IDO-mediated innate response, including the specific T cell regulatory subsets affected by IDO activity. Although the Trp catabolic pathway is shared between host and pathogen, the anabolic pathway is unique to A. fumigatus. The antifungals currently used in treatment are becoming increasingly ineffective with emerging drug resistant strains; therefore, drugs targeting essential fungal specific pathways are needed. A proposal for fungal treatment has been highlighted through the studies of essential amino acids. As AAA mutants are auxotrophs and decreased in virulence (28, 31), investigations of drugs targeting these pathway enzymes could lead to novel antifungal compounds. Indeed, a few compounds have exhibited some efficacy in targeting Trp metabolic pathways in M. tuberculosis and several fungi and efforts to identify additional inhibitors are warranted.

**AUTHOR CONTRIBUTIONS**

TC, TZ, and NK have made a substantial, direct, and intellectual contribution to the work and LR provided intellectual insights to the revision. All authors have approved it for publication.

**ACKNOWLEDGMENTS**

The authors would like to thank support from Dalai Lama Trust MSN178745 to TC, The Italian Grant “Programma per Giovani Ricercatori - Rita Levi Montalcini 2013” to TZ, and NIH 5R01AI065728-10 to NK.

**REFERENCES**

1. Segal BH, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol (2009) 47:528–90. doi:10.1080/13693780902736620

2. Keller NP. Heterogeneity confounds establishment of a model microbial strain. MBio (2017) 8:e00315–17. doi:10.1128/mBio.00315-17

3. Krappmann S, Bignell EM, Reichard U, Rogers T, Haynes K, Braus GH. The Aspergillus fumigatus transcriptional activator CpaC contributes significantly to the virulence of this fungal pathogen. Mol Microbiol (2004) 52:785–99. doi:10.1111/j.1365-2958.2004.04015.x

4. Amich J, Durnig M, O’keeffe G, Binder J, Doyle S, Beilhack A, et al. Exploration of sulfur assimilation of Aspergillus fumigatus reveals biosynthesis of sulfur-containing amino acids as a virulence determinant. Infect Immun (2016) 84:917–29. doi:10.1128/IAI01124-15

5. D’Enfert C, Diaquin M, Delit A, Wucher N, Debeauquis JP, Huerre M, et al. Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus. Infect Immun (1996) 64:4401–4.

6. Rhodes JC. Aspergillus fumigatus: growth and virulence. Med Mycol (2006) 44(Suppl 1):S77–81. doi:10.1080/13693780600779419

7. Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev (2009) 22:447–65. doi:10.1128/CMR.00053-08

8. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med (2016) 3:11. doi:10.3389/fmed.2016.00011

9. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global characterization of the ARO4 gene encoding a second DAHP synthase. Mol Microbiol (2010) 76:25–47. doi:10.1111/j.1365-2958.2010.07052.x
Ianiri G, Idnurm A. Essential gene discovery in the basidiomycete
Blanco B, Prado V, Lence E, Otero JM, Garcia-Doval C, Van Raaij MJ, et al.
Hu W, Sillaots S, Lemieux S, Davison J, Kauffman S, Breton A, et al.
Borgia PT, Dodge CL, Eagleton LE, Adams TH. Bidirectional gene transfer
Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
Sasse A, Hamer SN, Amich J, Binder J, Krappmann S. Mutant characterization
Duncan K, Edwards RM, Coggins JR. The pentafunctional AroM enzyme of
28. Wang PM, Choera T, Wiemann P, Pitsikul T, Amador-Noguez D, Keller NP.
27. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
26. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
25. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
24. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
23. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
22. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
21. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
20. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
19. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
18. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
17. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
16. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
15. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
14. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
13. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
12. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
11. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
10. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
9. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
8. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
7. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
6. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
5. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
4. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
3. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
2. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
1. Wang PM, Choera T, Wiemann P, Pisithkul T, Amador-Noguez D, Keller NP.
70. Yamazaki M, Fujimoto H, Kawasaki T. Chemistry of tremorogenic metabolites. Fumitremorgin A from Aspergillus fumigatus. Chem Pharm Bull (Tokyo) (1980) 28:245–54. doi:10.1248/cpb.28.2.245
71. Cole RJ. Fungal tremorgens. Prikli Biokhim Mikrobol (1993) 29:44–50.
72. Colangelo EJ. Cervicocranium and the aviator’s protective helmet. Aviat Space Environ Med (1975) 46:1263–4.
73. Zelante T, Fallarino F, Biston F, Puccetti P, Romani L. Indoleamine 2,3-dioxynegase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect (2009) 11:133–41. doi:10.1016/j.micinf.2008.10.007
74. Thomas SM, Garrity EF, Brandt CR, Schobert CS, Feng GS, Taylor MW, et al. IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxynegase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol (1993) 150:5529–34.
75. Aldajani WA, Salazar F, Sewell HF, Knox A, Ghaemmaghami AM. Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxynegase (IDO) by human airway epithelial cells and its effect on T cell activation. Oncotarget (2016) 7:57606–17. doi:10.18632/oncotarget.11586
76. De Luca A, Montagnoli C, Zelante T, Bonifazi P, Bozza S, Moretti S, et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol (2017) 199:5999–6008.
77. Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Belloccchio S, et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol (2005) 174:2910–8. doi:10.4049/jimmunol.174.5.2910
78. Bonifazi P, Zelante T, D’angelo C, De Luca A, Moretti S, Bozza S, et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 2:362–74. doi:10.1038/mi.2009.17
79. Cheng SC, Van De Venckon F, Smeekens S, Shobert CS, Feng GS, Taylor MW, et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer therapy. PLoS One (2015) 10:e0137423. doi:10.1371/journal.pone.0137423
80. PavegliosSA, AllardJ,FosterHodgkinsSR, AtherJL, Bevelander M, Campbell JM, et al. Airway epithelial indoleamine 2,3-dioxynegase inhibits CD4+ T cells during Aspergillus fumigatus antigen exposure. Am J Respir Cell Mol Biol (2011) 44:11–23. doi:10.1165/rcmb.2009-0167OC
81. De Luca A, Bozza S, Zelante T, Zagarella S, D’angelo C, Perruccio K, et al. Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO. Cell Mol Immunol (2010) 7:459–70. doi:10.4049/cmi.2010.10.43
82. Romani L, Fallarino F, De Luca A, Montagnoli C, D’angelo C, Zelante T, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature (2008) 451:211–5. doi:10.1038/nature06471
83. Iannitti RG, Carvalho A, Cunha C, De Luca A, Giovannini G, Casagrande A, et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxynegase deficiency but corrected by kynurenines. Am J Respir Crit Care Med (2013) 187:609–20. doi:10.1164/rccm.2012-1346OC
84. Araujo EF, Ferretti C, Galdino NA, Pretto NW, Calich VL, Loures FV. Tolerogenic plasmacytoid dendritic cells control Paracoccidioides brasiliensis infection by inducing regulatory T cells in an IDO-dependent manner. PLoS Pathog (2016) 12:e1006115. doi:10.1371/journal.ppat.1006115
85. Araujo EF, Loures FV, Basset SB, Ferretti C, Pina A, Schonassi AS, et al. Indoleamine 2,3-dioxynegase controls fungal loads and immunity in paracoccidioidomycosis but is more important to susceptible than resistant rats. Vet Res (2014) 45:e330. doi:10.1186/s13597-014-00330-0
86. Hage CA, Horan DJ, Durkin M, Connolly P, Desta Z, Sklar TC, et al. Histoplasma capsulatum preferentially induces IDO in the lung. Med Mycol (2013) 51:270–9. doi:10.3109/13693786.2012.710857
87. George MM, Subramanian Vignesh K, Landero Figueroa JA, Caruso JA, Deepi GS Jr. Zinc induces dendritic cell tolerogenic phenotype and skews regulatory T cell Th17 balance. J Immunol (2016) 197:1864–76. doi:10.4049/immunol.1604010
88. Gorski JP, Howard JB. Effect of methyamine on the structure and function of the fourth component of human complement, C4. J Biol Chem (1980) 255:10025–8.
89. Jung ID, Lee C-M, Jeong Y-I, Lee JS, Park WS, Han J, et al. Differential regulation of indoleamine 2,3-dioxynegase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett (2007) 581:1449–56. doi:10.1016/j.fsl.2007.02.073
90. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol (2009) 183:6303–12. doi:10.4049/jimmunol.0901577
91. Rivas FV, Chervonsky AV, Medichitov R. ART and immunology. Trends Immunol (2014) 35:451. doi:10.1016/j.it.2014.09.002
92. Soares MP, Gozzelino R, Weiss S. Tissue damage control in disease tolerance. Trends Immunol (2014) 35:483–94. doi:10.1016/j.it.2014.08.001
93. Romani L. Cell mediated immunity to fungi: a reassessment. Med Mycol (2008) 46:515–29. doi:10.1093/mmy/801971450
94. Zelante T, Bozza S, De Luca A, D’angelo C, Bonifazi P, Moretti S, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol (2009) 47(Suppl 1):S162–9. doi:10.1080/09602291.2008.1014766
95. Montagnoli C, Fallarino F, Gazzani R, Bozza S, Belloccchio S, Zelante T, et al. Immunology and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol (2006) 176:1712–23. doi:10.4049/jimmunol.176.3.1712
96. De Luca A, Pariano M, Cellini B, Costantini C, Villella VR, Jose SS, et al. The IL-17/IL-17R axis promotes respiratory allergy in the proximal airways. Cell Rep (2017) 20:1667–77. doi:10.1016/j.celrep.2017.07.063
97. De Ravan S, Zaremba KA, Long-Priel D, Chan KC, Fox SD, Gallin JJ, et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood (2010) 116:1755–60. doi:10.1182/blood-2009-07-233734
98. Macchiauzio A, Camaioni E, Nuti R, Pelliciari R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxynegase (IDO), a novel target in cancer therapy. Amino Acids (2009) 37:219–29. doi:10.1007/s00726-008-0137-3
99. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 37:2695–706. doi:10.1002/eji.200737409
100. Jiang N, Zhao GQ, Lin J, Hu L, Che C, Li C, et al. Indoleamine 2,3-dioxynegase is involved in the inflammation response of corneal epithelial cells to Aspergillus fumigatus infections. PLoS One (2015) 10:e0137423. doi:10.1371/journal.pone.0137423
in *Klebsiella pneumoniae* pneumonia. *J Immunol* (2014) 192:1778–86. doi:10.4049/jimmunol.1300039

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.